GSK (GSK) Scheduled to Post Quarterly Earnings on Wednesday
GSK (GSK) Scheduled to Post Quarterly Earnings on Wednesday
GSK (NYSE:GSK – Get Rating) is set to post its quarterly earnings results before the market opens on Wednesday, February 1st. Analysts expect GSK to post earnings of $0.59 per share for the quarter. GSK has set its FY 2022 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.
GSK（紐約證券交易所代碼：GSK — 獲取評級）將在 2 月 1 日（星期三）開市之前發布其季度收益業績。分析師預計 GSK 將在本季度發布每股 0.59 美元的盈利。GSK 已在 EPS 上設定了 2022 財年指引。有興趣註冊公司盈利電話會議的人員可以使用此連結進行註冊。
GSK (NYSE:GSK – Get Rating) last released its quarterly earnings data on Wednesday, November 2nd. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.19. The company had revenue of $9.22 billion during the quarter, compared to analyst estimates of $7.75 billion. GSK had a net margin of 37.88% and a return on equity of 32.18%. On average, analysts expect GSK to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
GSK (紐約證交所代碼:GSK — 獲得評分) 上次公佈其季度盈利數據，日期為 11 月 2 日（星期三）。該製藥公司報告了本季度每股盈利 1.09 美元，超過了 0.90 美元的共識估計值 0.19 美元。該公司在本季度的營收為 92.22 億美元，而分析師估計為 77.5 億美元。葛蘭素史克的淨利潤率為 37.88%，而股本回報率則為 32.18%。平均而言，分析師預計 GSK 在當前會計年度公布 3 美元的每股收益，下一個會計年度的每股收益為 3 美元。
GSK Stock Down 1.9 %
葛蘭素史克股票下跌 1.9%
Shares of NYSE GSK opened at $34.70 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.97 and a debt-to-equity ratio of 2.22. The firm has a market cap of $71.03 billion, a PE ratio of 4.25, a P/E/G ratio of 1.19 and a beta of 0.66. The company's fifty day simple moving average is $34.97 and its 200 day simple moving average is $34.54. GSK has a 12-month low of $28.47 and a 12-month high of $46.97.
紐約證券交易所 GSK 的股票週三開市為 34.70 美元。該公司的快速比率為 0.74，流動比率為 0.97，債務與權益比率為 2.22。該公司的市值為 71.03 億美元，私募股權比率為 4.25，盈利 E/G 比率為 1.19，貝塔值為 0.66。該公司的五十天簡單移動平均線為 34.97 美元，其 200 天簡單移動平均線為 34.54 美元。葛蘭素史克擁有十二個月低點 28.47 美元，而十二個月高點則為 46.97 元。
GSK Cuts Dividend
GSK 削減股息
Analysts Set New Price Targets
分析師設定新的價格目標
A number of analysts recently commented on the company. Barclays decreased their target price on GSK from GBX 1,800 ($22.29) to GBX 1,450 ($17.95) in a research report on Friday, October 14th. UBS Group lowered GSK from a "neutral" rating to a "sell" rating in a research report on Friday, November 11th. StockNews.com cut GSK from a "strong-buy" rating to a "buy" rating in a report on Wednesday, January 18th. AlphaValue raised shares of GSK to a "buy" rating in a research report on Thursday, December 8th. Finally, Bank of America lowered GSK from a "neutral" rating to an "underperform" rating in a research report on Monday, December 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $1,583.57.
一些分析師最近對該公司進行了評論。在 10 月 14 日（星期五）的一份研究報告中，巴克萊銀行將 GSK 的目標價格從 1,800 英鎊（22.29 美元）降至 1,450 英鎊（17.95 美元）。瑞銀集團 11 月 11 日（星期五）在研究報告中將 GSK 從「中立」評級降至「賣出」評級。在 1 月 18 日（週三）的一份報告中，Stocknews.com 將 GSK 從「強買入」評級降低為「買入」評級。AlphaValue 在 12 月 8 日（星期四）的研究報告中將 GSK 的股票提高到「買入」評級。最後，美國銀行在 12 月 5 日星期一的研究報告中將 GSK 從「中立」評級降至「表現不佳」評級。三位投資分析師對該股票的賣出評級進行了評級，其中六名分配了持有評級，三名則向該股發出買入評級。根據市場節拍的數據，該股的平均評級為「持有」，共識價格目標為 1,583.57 美元。
Institutional Inflows and Outflows
機構流入和流出
Hedge funds have recently added to or reduced their stakes in the stock. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company's stock valued at $42,000 after acquiring an additional 368 shares during the period. Fairfield Bush & CO. bought a new position in GSK in the 1st quarter valued at $80,000. Merit Financial Group LLC purchased a new position in shares of GSK during the 1st quarter valued at $238,000. Enlightenment Research LLC bought a new position in shares of GSK in the first quarter worth $244,000. Finally, Invesco Ltd. raised its position in shares of GSK by 6.9% in the first quarter. Invesco Ltd. now owns 6,418 shares of the pharmaceutical company's stock worth $280,000 after buying an additional 414 shares in the last quarter. Hedge funds and other institutional investors own 13.15% of the company's stock.
對沖基金最近增加或減少了他們在股票中的股份。納爾遜·范登堡和坎貝爾財富管理集團有限責任公司在第一季度將其在 GSK 股份中的地位提高了 61.3％。納爾遜·范登堡和坎貝爾財富管理集團有限責任公司現在擁有 968 股價值的製藥公司股票，價值為 $42,000 在此期間。費爾菲爾德·布什公司在第一季度在 GSK 買了一個新的位置，價值為 80,000 美元。美德金融集團有限責任公司在第一季度購買了 GSK 股份的新頭寸，價值為 238,000 美元。啟蒙研究有限責任公司在第一季度買了 GSK 股份的新位置，價值 244,000 美元。最後，景順有限公司在第一季度提高了 6.9% 的 GSK 股份地位。景順有限公司於上一季額外購入 414 股股份後，擁有該藥品公司股票價值 280,000 港元的 6,418 股。對沖基金和其他機構投資者擁有公司股票的 13.15%。
About GSK
關於葛蘭素史克
(Get Rating)
(取得評分)
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
GSK Plc 是一家醫療保健公司，從事醫藥、疫苗和消費性保健產品的研究、開發和製造。它通過以下部分運營：藥品; 藥品研發; 疫苗和消費者保健。藥品部門專注於開發呼吸系統疾病和傳染性疾病，腫瘤學和免疫炎症的藥物。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- 獲取有關 GSK（GSK）的研究報告的免費副本
- 高通公司從分析師那裡得到了推動力，但是是時候購買了嗎？
- eVGo 股票被收取以駕馭 EV 採用浪潮
- 高收益，深度價值 Verizon 放在底部
- 科蒂股票可以在 2023 年出現，具有上行空間
- 您應該用這種反向 ETF 投注納斯達克 100 嗎？
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
接收 GSK 每日新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 GSK 和相關公司的最新新聞和分析師評級的簡要每日摘要。